Introduction
The testis is considered an immunoprivileged site and has been investigated for its ability to protect cellular grafts from the host's immune system. [1] [2] [3] [4] This immunoprotective environment is due in part to the secretion of immunosuppressive molecules by Sertoli cells (SCs) [5] [6] [7] that allow ectopically transplanted SCs to survive as allografts [8] [9] [10] and concordant (rat-to-mouse) 11 and discordant (pig-to-rat) 12, 13 xenografts in rodents. In addition to the ability of transplanted SCs to protect themselves in immunologically foreign environments, SCs were shown to protect islets and neuronal cells from immunemediated rejection. 9, 10, [14] [15] [16] [17] [18] [19] The ability of SCs to protect themselves from immunemediated destruction, as well as their ability to produce a variety of proteins, has novel and potentially far-reaching implications for gene therapy. Gene therapy is an emerging field with the goal of replacing defective and deficient proteins to restore function in disease states. Traditionally, these therapies have involved the use of viral vectors or other methods to produce the expression (often transient) of the gene of interest, raising questions of safety and efficacy. [20] [21] [22] Cell-based gene therapy has been proposed as one means of overcoming these issues but has itself been hampered by the lack of an abundant, safe and immunologically acceptable source of the tissue. 21 Theoretically, transgenic animals can be designed to produce specific therapeutic proteins overcoming the issues of transient expression and safety associated with viral vectors, but this is hampered by immune rejection of the allogeneic or xenogeneic tissue. The use of transgenic SCs could overcome this issue by providing long-term gene expression in an immunoprivileged environment allowing the efficacious use of allogeneic or even xenogeneic cells. While the use of SCs to deliver therapeutic proteins has potential applications across numerous clinical situations, the greatest amount of data collected to date have been focused on diabetes and Parkinson's disease (PD). 9, 10, [14] [15] [16] [17] [18] [19] It is not our goal to review these data here; however, it seems intuitively obvious that the consistent ability to graft SCs in animal models of diabetes and PD successfully provides a strong foundation for further exploration of transgenic SCs in these same preclinical systems. For instance, islet transplantation for the treatment of type I diabetes was recently demonstrated to be a viable option. 23 However, in order to treat the majority of type I diabetic patients, two major problems must be overcome: elimination of the requirement for chronic immunosuppression needed to prevent human islet allograft destruction and an unlimited supply of insulin-producing tissue. The use of SCs engineered to produce insulin following appropriate stimulus would overcome both issues mentioned above. Similarly, this approach could be utilized for the treatment of PD since cotransplantation of SCs improved the engraftment of human neuronal cells when transplanted in hemi-Parkinsonian rat striatum. 19 In this study, we hypothesized that if SCs were engineered using transgenic technology to produce therapeutic proteins such as insulin or dopamine for the treatment of diseases such as diabetes or PD, then we could eliminate the need for immunosuppressive drugs and cotransplantation of cells. The results would enable us to overcome the major hurdles of gene therapy. In order to test this hypothesis, we used SCs isolated from transgenic mice engineered to produce green fluorescent protein (GFP) as a model and examined whether they would be able to survive allogeneic rejection and continue to express GFP.
Results

Characterization of SCs from TgN(GFPU)5Nagy mice
To verify the presence of GFP in SCs isolated from TgN(GFPU)5Nagy transgenic mice, testicular sections from TgN(GFPU)5Nagy and wild-type mice were immunostained for GFP (Figure 1a and b) . GFP-positive SCs were present in the TgN(GFPU)5Nagy but not in the wild-type testicular sections. To further verify the expression of GFP by SCs, seminiferous tubules and SCs were isolated from TgN(GFPU)5Nagy mouse testes and examined under blue-light fluorescence. An aliquot containing seminiferous tubules was collected during the isolation procedure after collagenase digestion. These tubules contained many GFP-expressing cells (Figure 1c ).
At the time of transplantation, SCs that had been cultured for 2 days to form aggregates were analyzed and also contained GFP-expressing cells (Figure 1d and e). Since the seminiferous tubules and aggregates contain other cells including germ cells and peritubular myoid cells, isolated cells were also cultured on chamber slides as a monolayer. SCs cultured in a monolayer can be identified by their characteristic morphology. These SCs expressed GFP (Figure 1f ). Nonetheless, it should be noted that not all of the cells from the TgN(GFPU)5Nagy mouse testes expressed GFP (Figure 1d ). SCs isolated from Balb/c mice were not fluorescent (data not shown).
Prior to transplantation, the composition of the transplanted cells was determined by assessing the proportion of immunoreactive GFP-or GATA-4-positive SCs and smooth muscle a-actin-positive peritubular myoid cells. 24 The cellular preparation was shown to contain 54.771.9% SCs and 2.870.6% myoid cells. Of the SCs, 66.173.3% were also GFP positive. The remaining cells were almost exclusively germ cells as determined by hematoxylin and eosin stain. Since germ cells are unable to survive at the higher temperature of the abdominal cavity, we did not expect them to survive after transplantation underneath the kidney capsule. 25 
Transplantation of TgN(GFPU)5Nagy SC aggregates to severe combined immunodeficient (SCID) mice
To assess whether SCs that produce GFP would be able to survive transplantation and continue to express the transgene, SC aggregates expressing GFP were transplanted under the left kidney capsule of Figure 1 Characterization of SCs from TgN(GFPU)5Nagy mice. Immunohistochemistry was performed on testicular sections from TgN(GFPU)5Nagy (a) and wild-type (b) mice (n ¼ 3) using a mouse monoclonal anti-GFP antibody followed by Cy3-conjugated goat anti-mouse secondary antibody. In addition, seminiferous tubules and SCs were isolated from TgN(GFPU)5Nagy mouse testes and examined under blue-light fluorescence for GFP expression. Seminiferous tubules (c), SCs that were cultured for 2 days to form aggregates prior to transplantation (d, e) and SCs cultured on chamber slides as a monolayer (f) (n ¼ 6 for each). Arrowhead, SC; arrow, SC aggregate. Bar in e, 100 mm for c-e; bar in f, 50 mm for a, b and f. To be certain that the GFP-positive cells detected in the grafts were SCs, sections from grafts 30 and 60 days posttransplant were double immunostained for GFP and GATA-4 (a marker for SCs). 24 GFP-positive SCs were present in 100% of the grafts at both 30 and 60 days posttransplant ( Figure 3) . However, not all of the SCs expressed GFP. This is consistent with the variable expression of GFP in the SCs from the TgN(GFPU)5Nagy mouse testes. The proportion of GFP-positive cells in the grafts was 46.674.4% GFP-positive SCs, 52.774.4% GFP-negative SCs and 0.870.5% GFP-positive cells that were a cell type other than SCs.
Transplantation of TgN(GFPU)5Nagy mouse islets to Balb/c mice
Prior to testing the survival of GFP-expressing SCs as allografts, it was first necessary to confirm that nonimmunoprivileged cells from the genetically undefined TgN(GFPU)5Nagy mice would be immunologically rejected by H-2 d Balb/c mice. Islets isolated from TgN(GFPU)5Nagy mice were transplanted to the renal subcapsular space of diabetic Balb/c mice, and all animals rejected these islets within 17 days, mean graft survival 14.7571.5 days7s.e. (Figure 4 ).
Transplantation of TgN(GFPU)5Nagy SC aggregates to Balb/c mice
To determine whether GFP-expressing SCs can survive as allografts and continue to produce the transgene, To confirm that the GFP-positive cells detected in the grafts were SCs, sections from grafts 30 and 60 days posttransplant were immunostained for GFP and/or GATA-4. When tissue sections were immunostained for GFP alone, positive cells were detected in six of the 10 grafts, while seven of the 10 grafts were positive when immunostained for GATA-4 alone. When sections were double stained for GFP and GATA-4, GFP-positive SCs were present in 50% of the grafts (Figure 6 ). Only a few infiltrating lymphocytes were present in the grafts. These data support the hypothesis that genetically engineered SCs can survive as allografts and express genes of interest.
Discussion
The use of transgenic tissue in gene therapy offers the advantages of long-term, stable expression of proteins without the safety concerns associated with viral vectors. However, issues of immune rejection prevent the widespread use of this tissue for transplantation. The ability of transgenic SCs to establish a locally immunoprivileged environment in transplant recipients could overcome these obstacles. The current study provides 'proof-ofprinciple' data of this concept by demonstrating that SCs obtained from transgenic mice engineered to produce GFP survived transplantation and continued to express GFP in both immunocompromised SCID mice and immunocompetent Balb/c mice for at least 60 days (ie the longest time point examined). Together these data suggest that SCs can be easily altered to express foreign proteins and that this expression does not inhibit the natural ability of SCs to protect themselves against allogeneic rejection.
In the current study, transgenic SCs exhibited robust GFP fluorescence in the native testis, as well as in vitro following enzymatic digestion from the testis and most importantly following transplantation into two different recipient animals. These data indicate that the expression of GFP in these animals is nontoxic to normal SC development and that the expression of the transgene can be maintained following conventional manipulation used for isolation and transplantation. The expression of GFP did not interfere with the SC's ability to protect itself from immune rejection as demonstrated by the fact that GFP-expressing SCs survived long-term in allogeneic recipients, while pancreatic islets were rapidly rejected. These data are all the more impressive considering the suggestion from previous work that the GFP protein itself is immunogenic. 26 When GFP-positive SCs were transplanted into SCID mice, 100% of the grafts survived as determined by both fluorescence microscopy and immunohistochemistry for GATA-4 (a marker for SCs). In contrast, the survival of GFP SCs in Balb/c mice was more variable with surviving SCs detected in 50-70% of the allografts. While the underlying reason for the variability is currently unknown, several factors likely contribute including the 
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need to optimize the isolation, culture and composition of SC grafts differentially across syngeneic-allogeneicxenogeneic barriers. In addition to these variables, future studies should also include a more detailed time-course analysis and large enough sample sizes to provide insight into the true variability associated with each approach. These studies must also consider the potential contribution of the therapeutic protein secreted to the process of immunological protection. These reservations withstanding, the present data provide the first successful reported example of a discordant cell-based transplant approach to gene therapy that does not require significant chemical or physical manipulation of the recipient's immune system.
Gene therapy has tremendous untapped medical potential, but has been mired in several practical and ethical problems. The major issue with the most common forms of gene therapy is identifying a vector that can safely, reproducibly and efficiently transfect nondividing cells. Most notable are the recent reports identifying the negative issues using adenoviral vectors as a means of inserting genes into cells. 22, 27 Other vectors have had similar unacceptable safety profiles, 21, 22 not to mention that the current vectors are limited as to the size of the gene constructs and hence, the types of proteins that can be generated.
On the other hand, the creation of stably transfected cells has been achieved by microinjections into the embryos. 28, 29 The development of transgenic animals has been well established for the study of a variety of diseases and for the production of human proteins for therapeutic purposes. [30] [31] [32] [33] [34] SCs have the capacity to engraft in various environments and produce a variety of proteins that are immunoprotective. In addition, these cells are naturally very prolific protein producers. Hence, the use of stably transfected SCs isolated from transgenic animals such as a pig could become an 'off-the-shelf' source of cells that not only protect themselves from immunedestruction but also produce therapeutic proteins.
In conclusion, this study demonstrates the ability of SCs isolated from transgenic animals to engraft and express a transgene in an animal model. These data have major implications for the field of gene therapy by providing a means of long-term delivery of crucial proteins needed to reverse disease states without immunosuppressive drugs and with minimal safety issues. Future studies will focus on the expression of therapeutically relevant protein expression and secretion by SCs to reverse a particular disease state.
Materials and methods
Animals
One heterozygous male TgN(GFPU)5Nagy mouse and one wild-type strain female mouse were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) as a breeding pair. TgN(GFPU)5Nagy mice created by germline transmission of a 129 ES line (H-2 b haplotype) were maintained by crossing with ICR (outbred) mice. 35 Male TgN(GFPU)5Nagy offspring were identified by the analysis of tail biopsies using a Zeiss fluorescent microscope and used as SC donors. Male SCID (Taconic Farms) and Balb/c (H-2 d haplotype; University of Alberta, Health and Laboratory Animal Services) mice, aged 6-8 weeks, were used as recipients.
SC isolation and characterization
SCs were isolated using a technique similar to that previously described for rat SCs. 9 . Briefly, testicles from adult male TgN(GFPU)5Nagy transgenic mice were surgically removed and placed in a 50 ml conical tube containing cold (41C) Hank's balanced salt solution (HBSS) supplemented with 0.25% (w/v) fraction V bovine serum albumin (BSA; Sigma Chemical Co., St Louis, MO, USA). The testes were cut into 1-mm fragments with scissors, digested for 6 min at 371C with collagenase Type V (2.5 mg/ml; Sigma) and then washed three times with HBSS. The tissue was resuspended in calcium-free medium supplemented with 1 mM EGTA and further digested with trypsin (25 mg/ml; Boehringer Mannheim, Laval, Canada) and DNase (4 mg/ml, Boehringer) for 10 min at 371C. The digest was passed Transplantation of GFP Sertoli cells JM Dufour et al through a 500-mm nylon mesh, washed with HBSS and cultured in nontreated Petri dishes (10 cm diameter) containing Ham's F10 media supplemented with 10 mmol/l D-glucose, 2 mmol/l L-glutamine, 50 mmol/l isobutylmethylxanthine, 0.5% BSA, 10 mmol/l nicotinamide, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf serum. Cells were incubated for 48 h at 371C to allow the formation of SC aggregates (100-300 mm diameter) before transplantation under the kidney capsule.
SC transplantation
Prior to transplantation, the purity and number of SCs was determined. Specifically, we assessed the number of GFP-or GATA-4-positive SCs and smooth muscle aactin-positive peritubular myoid cells in a representative aliquot after dissociation of the cell aggregates using techniques described previously. 24 In each preparation a minimum of 500 single cells were counted.
To determine the number of SCs isolated, three representative aliquots of the cell suspension were measured for total cellular DNA content using a Hoefer DyNa Quant 200 fluorometric assay (Amersham Pharmacia Biotech, San Francisco, CA, USA). Aliquots were washed with citrate buffer (150 mmol/l NaCl, 15 mmol/l citrate, 3 mmol/l EDTA, pH 7.4), resuspended in TNE buffer (10 mM Tris, 0.2 mM NaCl, 1 mM EDTA, pH 7.4) and sonicated. Aliquots of 10 ml were assayed in triplicate by diluting them in 2 ml of assay solution (0.1 mg/ml Hoechst 33258 in 1 Â TNE) and measuring fluorescence (365 nm excitation/460 nm emission). A sixpoint (0-500 ng/ml) DNA standard curve was generated using calf thymus DNA. For transplantation, aliquots consisting of 12.6877.95 million SCs as aggregates (6.6 pg DNA/cell) were aspirated into polyethylene tubing (PE-50), pelleted by centrifugation and gently placed under the left renal subcapsular space of Halothane-anesthetized SCID (n ¼ 6) and Balb/c (n ¼ 10) mice. 24 
Diabetic mice
Balb/c mice were rendered diabetic by intraperitoneal injection of streptozotocin (Streptozotocin, Sigma, St Louis, MO, USA) at a dose of 275 mg/kg body weight. Diabetes was confirmed by the presence of hyperglycemia and only those mice with nonfasting blood glucose levels exceeding 20 mM were used as recipients. Islets were isolated from TgN(GFPU)5Nagy mice by collagenase (Sigma, Type V) digestion, dextran gradient purification and subsequently cultured 24 h prior to transplantation of 500 TgN(GFPU)5Nagy mouse islets underneath the renal capsule of diabetic Balb/c mice. 9 After transplantation, nonfasting blood glucose levels were measured twice a week and graft rejection was defined as two successive blood glucose levels 414 mM.
Graft characterization
Nephrectomies were performed at 30 and 60 days posttransplant and the graft-bearing kidneys were examined immediately using blue-light fluorescent microscopy for GFP-expressing cells underneath the kidney capsule. Kidneys were then immersed in Z-fix and embedded in paraffin. After deparaffinization, and rehydration, sections were heated for 15 min in 0.01 M sodium citrate buffer (pH 6.0), in a microwave at full power.
9,24 Sections were incubated with 10% hydrogen peroxide to quench endogenous peroxidases, blocked with 1% BSA and single stained for GATA-4, or GFP or double stained for GATA-4 and GFP. For GATA-4, sections were incubated with goat polyclonal anti-GATA-4 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) primary antibody for 30 min, followed by biotinylated horse anti-goat secondary antibody for 20 min and diaminobenzamide as the chromagen using an ABC kit (Vector Laboratories, Burlingame, CA, USA). For GFP, sections were incubated with mouse monoclonal anti-GFP (1:100; Chemicon International, Inc., Temecula, CA, USA) primary antibody for 30 min, followed by Cy3-conjugated goat antimouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 20 min. GFP-positive cells were only detected in the grafts. No GFP-positive cells were present in the kidney.
